CA-NGINX
NGINX, Inc. , the company based on the popular open source project and offering a suite of technologies designed to develop and deliver modern applications, today announced general availability of its API Management Module. The API Management Module for NGINX Controller is part of the NGINX Application Platform, a modular and integrated set of technologies to help organizations create applications with performance, reliability, security, and scale. The NGINX API management solution enables infrastructure and operations (I&O) teams to define and publish APIs, manage traffic to and secure backend applications, monitor performance issues, and analyze API usage.
NGINX API Management Module is built on an innovative architecture that provides three unique benefits:
- Proven – NGINX combines new control-plane functionality with the raw power and efficiency of NGINX Plus, the industry’s most deployed API gateway. NGINX software powers more than 350 million websites and, according to our 2018 user survey, more than 40 percent of NGINX users have already deployed NGINX as an API gateway. NGINX is also a popular component in many traditional API management solutions, providing the underlying gateway for Axway, IBM DataPower, Kong, MuleSoft, Red Hat 3Scale, and others.
- Performance – NGINX eliminates the need for local databases and other additional components that introduce needless complexity, latency, and points of failure. Unlike traditional API management solutions, NGINX isolates API runtime traffic from API management traffic. As a result, the NGINX Plus API gateway (data plane) does not require constant connectivity to NGINX Controller (control plane). This reduces complexity and maximizes performance by reducing the average response time to serve an API call.
- Portable – Both NGINX Controller and NGINX Plus are flexible and can be deployed on any environment due to their small footprint – bare metal, VMs, containers, and public, private, and hybrid clouds. This versatility means you can use the NGINX API Management Module for both internal and external APIs. Easily deploy NGINX Plus in traditional environments to manage traffic for monolithic applications, as well as in containers to manage traffic among microservices in distributed applications.
"Our API management solution helps teams manage across the entire lifecycle of all their APIs without compromising performance. Our unique architecture is fast, flexible, and is well suited to the needs of both legacy and modern applications, especially for microservices," said Sidney Rabsatt, Vice President of Product Management at NGINX. "It saves time, reduces complexity, and lowers the cost of managing APIs."
Key API management capabilities include:
- API definition and publication – Provides a simple and intuitive interface to define APIs, manage upstream groups and backend servers, route resources to upstreams, and publish the resulting API definitions to NGINX Plus gateways.
- Authentication and authorization – Enables users to create and manage API keys, validate JWT to authenticate API consumers, share keys with API consumers, and import API keys from external systems.
- Rate limiting – Allows users to specify rate limits in order to mitigate DDoS attacks and protect applications. Leverages the new global rate limiting and clustering capabilities released in NGINX Plus R17.
- Visibility – Enables faster troubleshooting with deep visibility and critical insights into more than 200 advanced performance and transaction metrics for the APIs published through NGINX Plus API gateway instances.
- Multi -cloud support – Deploys on any public or private cloud to manage multiple NGINX Plus API gateway instances operating across a multi-cloud environment.
For an in-depth look and demo of the API Management Module for NGINX Controller, attend our webinar . To learn more or start your free trial, visit: https://www.nginx.com/products/nginx-controller/
About NGINX, Inc.
NGINX, Inc. is the company behind the popular open source project trusted by more than 350 million sites. We offer a suite of technologies for developing and delivering modern applications. The NGINX Application Platform enables enterprises undergoing digital transformation to modernize legacy, monolithic applications as well as deliver new, microservices-based applications. Companies like Netflix, Starbucks, and McDonalds rely on NGINX to reduce costs, improve resilience, and speed innovation. NGINX investors include Blue Cloud Ventures, e.ventures, Goldman Sachs, Index Ventures, MSD Capital, NEA, Runa Capital, and Telstra Ventures.
We are headquartered in San Francisco, CA, with our EMEA head office in Cork, Ireland and APAC head office in Singapore. Learn more at https://www.nginx.com/ or join the conversation by following @nginx on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005300/en/
Contact:
for NGINX, Inc. Caitlin Noll nginx@pancomm.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom